Characterization of Vascular Permeability-Increasing Component Isolated from Solid Tumors and the Effect of Highly Polymerized Dextran Sulfate on Its Activity

Abstract

Abstract-Increasein vascular permeability is usually seen at the growth site of a tumor implant in murine dermal tissue.Increased vascular permeability was inducible by the subcutaneous injection of a solid tumor extract rich in protein precipitable at 20-50% saturation of ammonium sulfate.The vascular permeability increasing activity of the tumor extract was reducible in the presence of highly polymerized dextran sulfate (DS-500) which showed a strong anti complementary activity, but not by other substances such as dextran sulfate with a low molecular weight, non-sulfated dextran, chondroitin sulfate or heparin.As the tumor extract includes r-globulins in aggregated or bound form and adsorbs complements, it is probable that the aggregated r-globulins increase vascular permeability by triggering the complement activation system in the skin. DS-500 might antagonize the process.

Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid–paclitaxel (CLA-PTX) on B16-F10 melanoma

“…When the tumor volume reached about 300 mm 3 , the tumor-bearing mice were randomly assigned to one of three groups: group 1 was given IV CLA-PTX solution, group 2 was given IV SSL-CLA-PTX, and group 3 was given IV iRGD-SSL-CLA-PTX. All the CLA-PTX preparations were injected through the tail veins at a dose of 2 mg CLA-PTX/kg.…”

“…When the tumor volume reached about 100-150 mm 3 , the tumor-bearing mice were randomly assigned to one of four groups: group 1 was given IV physiological saline as a control, group 2 was given IV CLA-PTX solution, group 3 was given IV SSL-CLA-PTX, and group 4 was given IV iRGD-SSL-CLA-PTX. Each group contained six animals.…”

“…Our results suggest that iRGD-modified SSLs, unlike Figure 9A, B effects of irgD-ssl-cla-PTX on the apoptosis of B16-F10 melanoma tumors. Notes: When the tumor volume reached about 100-150 mm 3 , the tumor-bearing c57Bl/6 mice were randomly assigned to one of four groups (each group contained six animals): group 1 was given intravenous (IV) physiological saline as a control, group 2 was given IV cla-PTX solution, group 3 was given IV ssl-cla-PTX, and group 4 was given IV irgD-ssl-cla-PTX. all the cla-PTX preparations were injected through the tail veins at a dose of 2 mg cla-PTX/kg on days 7, 9, 11, 13, and 15.…”

“…3,4 Conversion of PTX into a water-soluble conjugate is an important alternative strategy. [5][6][7][8] Examples of this include the poly(L-glutamic acid)-PTX conjugate (coded as CT-2103), polyethylene glycol (PEG)-PTX conjugate, hyperbranched poly(ether-ester)-PTX conjugate, poly(L-γ-glutamyl-glutamine)-PTX conjugate, N-(2-hydroxypropyl)-methacrylamide-PTX conjugate, PEG-polylactic acid-PTX, and hyaluronic acid-PTX conjugate.…”

Mouse Ly-gene Haplotypes and Subcutaneous Regression of Ehrlich Ascites Tumor

“…The subdermal setting seems to magnify host responsiveness to EAT. As inflammatory responses, involving leukocytes and activated macrophage migration as well as immunoglobulin accumulation, take place at the dermal site injected with EAT [10][11][12], rejection reactions against EAT might be amplified at the local site.…”